Abstract | OBJECTIVE: STUDY DESIGN: Eligible patients received either a single intravenous dose of 50 microg/kg anti-D (anti-D50), 75 microg/kg anti-D, (anti-D75), or 0.8 g/kg IVIg, ( IVIg). Patients were monitored for response to treatment and adverse events. RESULTS: By 24 hours after treatment 50%, 72%, and 77% of patients in the anti-D50, anti-D75, and IVIg groups, respectively, had achieved a platelet count>20,000/microL (P=.03). By day 7, hemoglobin concentrations decreased by 1.6 g/dL, 2 g/dL, and 0.3 g/dL in the anti-D50, anti-D75, and IVIg groups, respectively. Headache, fever, or chills occurred least often in the anti-D50 group. CONCLUSIONS:
|
Authors | Michael D Tarantino, Guy Young, Salvatore J Bertolone, Karen A Kalinyak, Frank E Shafer, Roshni Kulkarni, Lisa C Weber, Mary L Davis, Henry Lynn, Diane J Nugent, Acute ITP Study Group |
Journal | The Journal of pediatrics
(J Pediatr)
Vol. 148
Issue 4
Pg. 489-94
(Apr 2006)
ISSN: 0022-3476 [Print] United States |
PMID | 16647411
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Immunoglobulins, Intravenous
- Immunologic Factors
- Rho(D) Immune Globulin
|
Topics |
- Adolescent
- Child
- Child, Preschool
- Dose-Response Relationship, Drug
- Female
- Humans
- Immunoglobulins, Intravenous
(therapeutic use)
- Immunologic Factors
(administration & dosage, adverse effects, pharmacology)
- Infant
- Male
- Platelet Count
- Prospective Studies
- Purpura, Thrombocytopenic, Idiopathic
(blood, drug therapy)
- Rho(D) Immune Globulin
(administration & dosage, adverse effects, pharmacology)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|